MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 259 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.47 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,302,540 | +84.9% | 29,635 | +76.3% | 0.00% | +100.0% |
Q1 2024 | $4,489,137 | -71.8% | 16,811 | -75.6% | 0.00% | -80.0% |
Q4 2023 | $15,938,520 | +191.7% | 68,885 | +84.1% | 0.01% | +150.0% |
Q3 2023 | $5,463,743 | +21.2% | 37,413 | +91.7% | 0.00% | +100.0% |
Q2 2023 | $4,508,808 | +16.0% | 19,519 | +21.7% | 0.00% | 0.0% |
Q1 2023 | $3,886,250 | -47.6% | 16,041 | -37.2% | 0.00% | -50.0% |
Q4 2022 | $7,409,502 | +339.2% | 25,528 | -1.6% | 0.00% | +100.0% |
Q3 2022 | $1,687,000 | -26.8% | 25,953 | -19.4% | 0.00% | 0.0% |
Q2 2022 | $2,306,000 | -3.7% | 32,208 | +32.0% | 0.00% | 0.0% |
Q1 2022 | $2,394,000 | +0.5% | 24,403 | -13.2% | 0.00% | 0.0% |
Q4 2021 | $2,382,000 | +4.1% | 28,104 | -2.0% | 0.00% | 0.0% |
Q3 2021 | $2,288,000 | -24.2% | 28,665 | -7.4% | 0.00% | 0.0% |
Q2 2021 | $3,017,000 | -24.0% | 30,970 | -8.8% | 0.00% | 0.0% |
Q1 2021 | $3,971,000 | -18.6% | 33,951 | -22.6% | 0.00% | 0.0% |
Q4 2020 | $4,879,000 | +421.3% | 43,891 | +456.7% | 0.00% | – |
Q3 2020 | $936,000 | -15.2% | 7,884 | -19.1% | 0.00% | – |
Q2 2020 | $1,104,000 | +105.6% | 9,750 | +21.4% | 0.00% | – |
Q1 2020 | $537,000 | -45.4% | 8,034 | -25.5% | 0.00% | – |
Q4 2019 | $983,000 | +22.1% | 10,779 | +15.6% | 0.00% | – |
Q3 2019 | $805,000 | +7.2% | 9,326 | +30.2% | 0.00% | – |
Q2 2019 | $751,000 | -8.4% | 7,164 | +9.5% | 0.00% | – |
Q1 2019 | $820,000 | +59.2% | 6,545 | +43.3% | 0.00% | – |
Q4 2018 | $515,000 | -82.5% | 4,568 | -66.8% | 0.00% | -100.0% |
Q3 2018 | $2,944,000 | +4.8% | 13,749 | +36.9% | 0.00% | 0.0% |
Q2 2018 | $2,808,000 | +203.2% | 10,040 | +26.6% | 0.00% | – |
Q1 2018 | $926,000 | +27.5% | 7,928 | +0.3% | 0.00% | – |
Q4 2017 | $726,000 | +3721.1% | 7,901 | +1785.7% | 0.00% | – |
Q3 2017 | $19,000 | +850.0% | 419 | +215.0% | 0.00% | – |
Q2 2017 | $2,000 | 0.0% | 133 | +3.9% | 0.00% | – |
Q1 2017 | $2,000 | 0.0% | 128 | 0.0% | 0.00% | – |
Q4 2016 | $2,000 | 0.0% | 128 | 0.0% | 0.00% | – |
Q3 2016 | $2,000 | – | 128 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paulson & Co. | 1,850,000 | $518,296,000 | 38.31% |
Tao Capital Management LP | 130,529 | $36,569,005 | 29.98% |
University of Wisconsin Foundation | 45,730 | $12,811,717 | 14.42% |
AlpInvest Partners B.V. | 84,595 | $23,700,135 | 8.50% |
RTW INVESTMENTS, LP | 1,915,862 | $536,747,898 | 8.31% |
Propel Bio Management, LLC | 43,032 | $12,055,845 | 7.82% |
Avoro Capital Advisors LLC | 2,055,555 | $575,884,289 | 7.67% |
Baker Brothers Advisors | 1,974,590 | $553,201,134 | 7.07% |
Tri Locum Partners LP | 65,352 | $18,309,016 | 4.63% |
TCG Crossover Management, LLC | 149,283 | $41,823,125 | 4.36% |